Literature DB >> 24976810

Telemanagement for inflammatory bowel disease.

Raymond K Cross1.   

Abstract

Entities:  

Year:  2014        PMID： 24976810      PMCID： PMC4073538     

Source DB:  PubMed          Journal:  Gastroenterol Hepatol (N Y)        ISSN： 1554-7914


× No keyword cloud information.
  6 in total

1.  Acceptance of telemanagement is high in patients with inflammatory bowel disease.

Authors:  Raymond K Cross; Mohit Arora; Joseph Finkelstein
Journal:  J Clin Gastroenterol       Date:  2006-03       Impact factor: 3.062

2.  E-health empowers patients with ulcerative colitis: a randomised controlled trial of the web-guided 'Constant-care' approach.

Authors:  Margarita Elkjaer; Mary Shuhaibar; Johan Burisch; Yvonne Bailey; Hanne Scherfig; Birgit Laugesen; Søren Avnstrøm; Ebbe Langholz; Colm O'Morain; Elsebeth Lynge; Pia Munkholm
Journal:  Gut       Date:  2010-12       Impact factor: 23.059

3.  Randomized, controlled trial of home telemanagement in patients with ulcerative colitis (UC HAT).

Authors:  Raymond K Cross; Nadia Cheevers; Ankur Rustgi; Patricia Langenberg; Joseph Finkelstein
Journal:  Inflamm Bowel Dis       Date:  2011-06-17       Impact factor: 5.325

4.  Feasibility and acceptance of a home telemanagement system in patients with inflammatory bowel disease: a 6-month pilot study.

Authors:  Raymond K Cross; Joseph Finkelstein
Journal:  Dig Dis Sci       Date:  2007-01-09       Impact factor: 3.199

5.  Potential use of telemedicine to provide outpatient care for inflammatory bowel disease.

Authors:  Michael Krier; Tonya Kaltenbach; Kenneth McQuaid; Roy Soetikno
Journal:  Am J Gastroenterol       Date:  2011-12       Impact factor: 10.864

6.  Association between telephone activity and features of patients with inflammatory bowel disease.

Authors:  Claudia Ramos-Rivers; Miguel Regueiro; Eric J Vargas; Eva Szigethy; Robert E Schoen; Michael Dunn; Andrew R Watson; Marc Schwartz; Jason Swoger; Leonard Baidoo; Arthur Barrie; Anwar Dudekula; Ada O Youk; David G Binion
Journal:  Clin Gastroenterol Hepatol       Date:  2013-11-19       Impact factor: 11.382
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.